Giuseppe Toffoli
Experimental and Clinical Pharmacology Unit
Centro di Riferimento Oncologico National Cancer Institute
via Pedemontana Occidentale 12
Aviano 33081
Italy
Name/email consistency: high
- Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. Toffoli, G., Cecchin, E., Gasparini, G., D'Andrea, M., Azzarello, G., Basso, U., Mini, E., Pessa, S., De Mattia, E., Lo Re, G., Buonadonna, A., Nobili, S., De Paoli, P., Innocenti, F. J. Clin. Oncol. (2010)
- Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Toffoli, G., Biason, P., Russo, A., De Mattia, E., Cecchin, E., Hattinger, C.M., Pasello, M., Alberghini, M., Ferrari, C., Scotlandi, K., Picci, P., Serra, M. Clin. Cancer Res. (2009)
- Pharmacogenetic relevance of MTHFR polymorphisms. Toffoli, G., De Mattia, E. Pharmacogenomics (2008)
- Pharmacology of epidermal growth factor inhibitors. Toffoli, G., De Mattia, E., Cecchin, E., Biason, P., Masier, S., Corona, G. Int. J. Biol. Markers (2007)
- Pharmacogenetics and stomach cancer: an update. Toffoli, G., Cecchin, E. Pharmacogenomics (2007)
- Clinical implications of genetic polymorphisms on stomach cancer drug therapy. Toffoli, G., Cecchin, E. Pharmacogenomics J. (2007)
- The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L.M., Pessa, S., Errante, D., De Pangher, V., Giusto, M., Medici, M., Gaion, F., Sandri, P., Galligioni, E., Bonura, S., Boccalon, M., Biason, P., Frustaci, S. J. Clin. Oncol. (2006)
- Pharmacokinetic optimisation of treatment with oral etoposide. Toffoli, G., Corona, G., Basso, B., Boiocchi, M. Clin. Pharmacokinet (2004)
- Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin. Toffoli, G., Sorio, R., Basso, B., Aita, P., Corona, G., Rupolo, M., Ruolo, G., Boiocchi, M. J. Chemother (2004)
- Pharmacogenomics and stomach cancer. Toffoli, G., Cecchin, E. Pharmacogenomics (2004)
- Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Toffoli, G., Corona, G., Cattarossi, G., Boiocchi, M., Di Gennaro, G., Tirelli, U., Vaccher, E. Ann. Oncol. (2004)
- Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. Toffoli, G., Cecchin, E. J. Chemother (2004)
- Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Toffoli, G., Russo, A., Innocenti, F., Corona, G., Tumolo, S., Sartor, F., Mini, E., Boiocchi, M. Int. J. Cancer (2003)
- Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. Toffoli, G., Gafà, R., Russo, A., Lanza, G., Dolcetti, R., Sartor, F., Libra, M., Viel, A., Boiocchi, M. Clin. Cancer Res. (2003)
- Pharmacogenetics of irinotecan. Toffoli, G., Cecchin, E., Corona, G., Boiocchi, M. Curr. Med. Chem. Anticancer. Agents (2003)
- Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Toffoli, G., Rossi, D., Gaidano, G., Cecchin, E., Boiocchi, M., Carbone, A. Int. J. Biol. Markers (2003)
